logo
#

Latest news with #ClaimVantage

High Growth Tech Stocks In The US Market To Watch
High Growth Tech Stocks In The US Market To Watch

Yahoo

time23-05-2025

  • Business
  • Yahoo

High Growth Tech Stocks In The US Market To Watch

As the U.S. market experiences a slight dip following a strong rally in the S&P 500, investors are closely monitoring economic indicators and broader market sentiment that impact small-cap companies. In this environment, identifying high-growth tech stocks involves looking for companies with robust earnings potential and resilience to economic fluctuations, making them noteworthy candidates in today's dynamic landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ Legend Biotech 26.73% 58.77% ★★★★★★ Travere Therapeutics 25.82% 65.45% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.65% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★☆ Overview: Vertex, Inc. offers enterprise tax technology solutions for retail, wholesale, and manufacturing sectors globally and has a market capitalization of approximately $6.05 billion. Operations: Vertex, Inc. generates revenue primarily from its software and programming segment, which accounts for $687.06 million. Vertex's recent strategic partnership with Majesco, integrating its tax solutions into the ClaimVantage platform, underscores its commitment to enhancing operational efficiency and accuracy in tax calculations for disability claims. This move not only boosts Vertex's service offerings but also expands its market reach in Canada with plans to extend to U.S. customers later this year. Financially, Vertex reported a significant increase in Q1 2025 revenue, rising to $177.06 million from $156.78 million the previous year, alongside a substantial growth in net income from $2.68 million to $11.13 million. These figures reflect Vertex's robust financial health and innovative edge in developing solutions that address complex regulatory challenges, positioning it well for future expansion and profitability as indicated by their optimistic revenue forecasts of up to $768 million for 2025. Navigate through the intricacies of Vertex with our comprehensive health report here. Assess Vertex's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $3.58 billion. Operations: Sarepta Therapeutics focuses on discovering, developing, manufacturing, and delivering RNA-targeted therapeutics and gene therapies for rare diseases, generating $2.23 billion in revenue. Sarepta Therapeutics, a trailblazer in gene therapies for Duchenne muscular dystrophy, recently showcased promising results from its ENDEAVOR study. Treatment with ELEVIDYS demonstrated significant dystrophin protein expression, a crucial factor for disease management. Despite facing challenges such as elevated liver enzymes in some patients, Sarepta's rigorous monitoring and adaptive treatment strategies underscore its commitment to safety and efficacy. The company's strategic focus on innovative gene therapies not only enhances its portfolio but also positions it well within the high-growth biotech sector, despite a recent downward adjustment in revenue projections to $2.3 billion for 2025. Unlock comprehensive insights into our analysis of Sarepta Therapeutics stock in this health report. Gain insights into Sarepta Therapeutics' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ciena Corporation is a network technology company that offers hardware, software, and services to network operators across multiple regions including the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and India with a market capitalization of approximately $11.55 billion. Operations: Ciena generates revenue primarily from its Networking Platforms segment, which accounts for $3.06 billion, followed by Global Services at $540.45 million. The Platform Software and Services and Blue Planet Automation Software and Services segments contribute $363.38 million and $89.71 million, respectively. Despite a challenging year with earnings growth down by 64.7%, Ciena's commitment to innovation remains robust, as evidenced by its significant R&D investment and recent technological advancements. The company has successfully trialed its WaveLogic 6 Extreme technology over an impressive distance of 1,590 kilometers, showcasing potential for future high-bandwidth applications. This aligns with a revenue growth forecast of 9.4% annually, outpacing the US market average of 8.5%. With earnings expected to surge by 51% annually, Ciena is strategically positioned to capitalize on increasing demand for advanced network solutions, despite current profit margins standing at a modest 2%. Click here to discover the nuances of Ciena with our detailed analytical health report. Review our historical performance report to gain insights into Ciena's's past performance. Reveal the 234 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:VERX NasdaqGS:SRPT and NYSE:CIEN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

High Growth Tech Stocks In The US Market To Watch
High Growth Tech Stocks In The US Market To Watch

Yahoo

time20-05-2025

  • Business
  • Yahoo

High Growth Tech Stocks In The US Market To Watch

As the U.S. market experiences a slight dip following a strong rally in the S&P 500, investors are closely monitoring economic indicators and broader market sentiment that impact small-cap companies. In this environment, identifying high-growth tech stocks involves looking for companies with robust earnings potential and resilience to economic fluctuations, making them noteworthy candidates in today's dynamic landscape. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Ardelyx 20.57% 59.97% ★★★★★★ Legend Biotech 26.73% 58.77% ★★★★★★ Travere Therapeutics 25.82% 65.45% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.65% 61.11% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.16% 60.26% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★☆ Overview: Vertex, Inc. offers enterprise tax technology solutions for retail, wholesale, and manufacturing sectors globally and has a market capitalization of approximately $6.05 billion. Operations: Vertex, Inc. generates revenue primarily from its software and programming segment, which accounts for $687.06 million. Vertex's recent strategic partnership with Majesco, integrating its tax solutions into the ClaimVantage platform, underscores its commitment to enhancing operational efficiency and accuracy in tax calculations for disability claims. This move not only boosts Vertex's service offerings but also expands its market reach in Canada with plans to extend to U.S. customers later this year. Financially, Vertex reported a significant increase in Q1 2025 revenue, rising to $177.06 million from $156.78 million the previous year, alongside a substantial growth in net income from $2.68 million to $11.13 million. These figures reflect Vertex's robust financial health and innovative edge in developing solutions that address complex regulatory challenges, positioning it well for future expansion and profitability as indicated by their optimistic revenue forecasts of up to $768 million for 2025. Navigate through the intricacies of Vertex with our comprehensive health report here. Assess Vertex's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $3.58 billion. Operations: Sarepta Therapeutics focuses on discovering, developing, manufacturing, and delivering RNA-targeted therapeutics and gene therapies for rare diseases, generating $2.23 billion in revenue. Sarepta Therapeutics, a trailblazer in gene therapies for Duchenne muscular dystrophy, recently showcased promising results from its ENDEAVOR study. Treatment with ELEVIDYS demonstrated significant dystrophin protein expression, a crucial factor for disease management. Despite facing challenges such as elevated liver enzymes in some patients, Sarepta's rigorous monitoring and adaptive treatment strategies underscore its commitment to safety and efficacy. The company's strategic focus on innovative gene therapies not only enhances its portfolio but also positions it well within the high-growth biotech sector, despite a recent downward adjustment in revenue projections to $2.3 billion for 2025. Unlock comprehensive insights into our analysis of Sarepta Therapeutics stock in this health report. Gain insights into Sarepta Therapeutics' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ciena Corporation is a network technology company that offers hardware, software, and services to network operators across multiple regions including the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and India with a market capitalization of approximately $11.55 billion. Operations: Ciena generates revenue primarily from its Networking Platforms segment, which accounts for $3.06 billion, followed by Global Services at $540.45 million. The Platform Software and Services and Blue Planet Automation Software and Services segments contribute $363.38 million and $89.71 million, respectively. Despite a challenging year with earnings growth down by 64.7%, Ciena's commitment to innovation remains robust, as evidenced by its significant R&D investment and recent technological advancements. The company has successfully trialed its WaveLogic 6 Extreme technology over an impressive distance of 1,590 kilometers, showcasing potential for future high-bandwidth applications. This aligns with a revenue growth forecast of 9.4% annually, outpacing the US market average of 8.5%. With earnings expected to surge by 51% annually, Ciena is strategically positioned to capitalize on increasing demand for advanced network solutions, despite current profit margins standing at a modest 2%. Click here to discover the nuances of Ciena with our detailed analytical health report. Review our historical performance report to gain insights into Ciena's's past performance. Reveal the 234 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:VERX NasdaqGS:SRPT and NYSE:CIEN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Majesco and Vertex Announce Partnership to Deliver Advanced Tax Solutions for Disability Claims and Absence Management
Majesco and Vertex Announce Partnership to Deliver Advanced Tax Solutions for Disability Claims and Absence Management

Business Wire

time07-05-2025

  • Business
  • Business Wire

Majesco and Vertex Announce Partnership to Deliver Advanced Tax Solutions for Disability Claims and Absence Management

MORRISTOWN, N.J.--(BUSINESS WIRE)--Majesco, a global leader in cloud insurance software solutions, is excited to announce a partnership with Vertex Inc., a global provider of indirect tax technology solutions. This partnership introduces the Majesco ClaimVantage solution utilizing Vertex tax expertise, delivering a transformative tax solution designed to empower customers with a comprehensive, seamless, and automated tax calculation solution for disability claims and absence management. Since 1978, Vertex has been at the forefront of tax technology, helping businesses with tax determination and compliance. Respected for its expertise in complex tax systems, the company offers businesses the confidence to transact, comply and grow with confidence. Vertex Payroll Tax, a SaaS-based solution, calculates gross-to-net payroll tax deductions for the U.S. and Canada, helping businesses simplify complex tax calculations. 'As a leading payroll engine supporting the payroll needs of over 33 million employees, we are excited to welcome Majesco into the Vertex Payroll family,' said Michael Schuster, Principal Product Manager at Vertex Inc. 'We look forward to collaborating with their team and delivering accurate, reliable tax calculations to their clients.' The integration of Vertex's payroll tax engine into Majesco ClaimVantage solutions offers Canadian carriers and third-party administrators (TPAs) a robust, seamless tax calculation and payment solution as part of their disability claims and absence management workflows. Key Highlights of the ClaimVantage with Vertex Solution: Robust Tax Solution: With integration from an industry leader in indirect tax and compliance, Majesco now offers seamless and more accurate tax calculations for disability claims and absence management. Out-of-the-Box Plug and Play: As a pre-built integration, the implementation of the ClaimVantage with Vertex solution is quick and straightforward, enabling seamless integration into existing systems with minimal disruption. Always Up to Date: With Vertex's continual tax content updates, tax parameters are automatically refreshed, helping ensure that payment calculations align with the latest specifications and regulations. Benefits of the ClaimVantage with Vertex solution: Accuracy: The integration helps ensure tax calculation accuracy for customers, with no need for annual updates – keeping all calculations aligned with current specifications. Efficiency: Claims teams benefit from automated tax calculations, improving operational efficiency and reducing manual errors. Simplicity: The effortless nature of the integration helps ensure a seamless experience for users, streamlining operations with minimal setup. 'Majesco is thrilled to introduce the ClaimVantage with Vertex solution, a transformative partnership that enables customers with a comprehensive tax solution,' said Ray Law, SVP & GM, Product at Majesco. 'By integrating Vertex's advanced tax technology, our customers' claims teams can achieve unparalleled efficiency and benefit from a simple, streamlined implementation. As we move forward with this powerful partnership, we're excited to see how it will positively impact our customers' operations.' Majesco plans to extend the Vertex integration to U.S. customers later this year, making the Vertex tax solution the new standard for users, offering a more streamlined and efficient experience for claims and absence management. About Majesco Majesco is the partner P&C and L&AH insurers choose to create and deliver outstanding experiences for customers. We combine our technology and insurance experience to anticipate what is next, without losing sight of what's important now. Over 350 insurers, from MGAs, greenfields and startups to some of the world's largest insurers and reinsurers, rely on Majesco's intelligent SaaS platforms solutions, with GenAI powered insurance data analytics, of core, data, analytics, distribution, underwriting, loss control, digital, and rich ecosystem of partners to create their next now. As an industry leader, we don't believe in managing risk by avoiding change. We embrace change, even cause it, to get and stay ahead of risk. With 1000+ successful implementations and 90% of our customers in the cloud we are uniquely qualified to bridge the gap between a traditional insurance industry approach and a pure digital mindset. We give customers the confidence to decide, the products to perform, and the follow-through to execute.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store